Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Novocure Dipped 19% This Week

By Cory Renauer – Jul 30, 2021 at 4:22PM

Key Points

  • The company recently reported second-quarter revenue missed consensus expectations.
  • The number of patients using the company's cancer therapy isn't rising very fast.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Uptake of the company's revolutionary disease-controlling device isn't progressing as quickly as expected.

What happened

Shares of Novocure (NVCR -0.70%) slid this week in response to a disappointing second-quarter earnings report. Investors aren't happy about the slower-than-anticipated rollout of the company's Tumor Treating Fields, or TTF, therapy. The healthcare stock finished the week down 18.7% from its closing price last Friday. 

So what 

During the three months ended June 30, Novocure reported total revenue rose 23% year over year to $133.5 million, which was around $8.3 million less than consensus estimates. It was also slightly less than the company reported during the first three months of the year.

Scientists in a lab.

Image source: Getty Images.

Investors were also disturbed by the lack of new patients using the company's devices to stop their tumors from growing. Active patients rose 6% year over year to 3,487, but this was just 34 more than the company reported at the end of March.

Now what

Novocure began marketing its TTF device Optune for patients with an aggressive form of brain cancer, called glioblastoma multiforme, in 2011. In 2015, the FDA expanded Optune's addressable patient population to include newly diagnosed GBM patients. 

By the company's estimates, around 8,200 patients with GBM seek treatment in the U.S. every year. In other words, Optune has probably reached a saturation point with its currently available patient pool.

Novocure is working hard to grow Optune's addressable patient population but it hasn't been easy. On July 1, the company reported disappointing results from a liver cancer study. Investigators were looking for a response rate of 20% or higher, but treatment with Optune plus standard care shrank tumors for just 9.5% of patients.

Novocure's next chances at expanding beyond the limited mesothelioma and GBM niches are coming up soon. The company is currently enrolling non-small cell lung cancer (NSCLC) patients into a phase 2 combination trial with Keytruda, a blockbuster cancer therapy from Merck. In 2022, the company also expects to read out results from an ongoing phase 3 NSCLC trial. 

In the U.S. last year, NSCLC claimed more than 100,000 lives and many more patients received their first diagnosis. Impressive trial data among this gigantic population could allow this beaten-down healthcare stock to bounce back stronger than ever.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Novocure. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novocure Stock Quote
$75.00 (-0.70%) $0.53
Merck & Co. Stock Quote
Merck & Co.
$107.50 (0.64%) $0.68

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.